Medical and traumatic emergency conditions affecting the cardiac, respiratory, nervous, and hematologic systems
collectively account for the overwhelming preponderance of death and disability affecting Americans. It is imperative that
new approaches for timely diagnosis and treatment of these conditions treatments be efficiently developed.
This application is to form a Southern California Strategies to Innovate EmeRgENcy Care Clinical Trials
Network (SoCal SIREN) Hub and Spoke system that will conduct high-quality, multi-site clinical trials to improve the
outcomes for patients with neurologic, cardiac, respiratory, and hematologic, and trauma emergency events. The SoCal
SIREN consortium will marshal all six academic medical centers in the region (UCLA, Harbor-UCLA, USC, UCI,
UCSD, and Cedars-Sinai); all 3 County EMS agencies [Los Angeles EMS (lead), Orange County EMS (co-lead), and San
Diego County EMS (flexible)], and up to 83 potential performance sites (1 Hub, 5 Core Spoke, 16 Additional Spoke, and
61 Flexible Spoke) Medical Centers in Southern California, experienced in performing emergency clinical trials
efficiently and excellently. Eleven Advisory Panels with expertise in specific disease and research domains will facilitate
trial implementation within the Network and serve as a resource to the Hub leadership and to individual performance sites.
The four specific aims of this proposal are to: 1) perform high-quality pragmatic clinical trials in several different
types of emergency disorders afflicting adults or children throughout Southern California; 2) facilitate collaboration
between emergency medicine physicians and disease specialists throughout Southern California in trial design and
execution high quality NSTN recovery and rehabilitaiton trials throughout Los Angeles and Orange Counties; 3) facilitate
collaboration between the prehospital EMS system and acute receiving hospitals, including specialty receiving centers in
trauma, stroke, and cardiac resuscitation, throughout Southern California in trial design and execution; and 4) ensure
participation of a substantial number of patients with emergency conditions in SIREN clinical trials, including women,
children, Hispanic-Americans, African-Americans, and other traditionally underrepresented populations.